Molecular Engineering Strategies Tailoring the Apoptotic Response to a MET Therapeutic Antibody
Chiara Modica(Candiolo Cancer Institute), Elisa Vigna(Candiolo Cancer Institute)
Cited by 3
Related Papers
Monovalency Unleashes the Full Therapeutic Potential of the DN-30 Anti-Met Antibody
|Journal of Biological Chemistry|2010|77
Dual Constant Domain‐Fab: A novel strategy to improve half‐life and potency of a Met therapeutic antibody
|Molecular Oncology|2016|14
A receptor-antibody hybrid hampering MET-driven metastatic spread
|Journal of Experimental & Clinical Cancer Research|2021|11